Tzu-Fei Wang
Scientist, Inflammation and Chronic Disease
Ottawa Hospital Research Institute
Associate professor, Division of Hematology, Department of Medicine
University of Ottawa
Research Interests
Cancer-associated Venous thromboembolism, including prevention and management strategies
Obesity related thromboembolism and anticoagulant strategies
Drug-drug interactions with anticoagulants
Brief Biography
Tzu-Fei Wang, MD, MPH is a hematologist and an associate professor in the Division of Hematology, Department of Medicine at the University of Ottawa and the Ottawa Hospital and a Scientist at the Ottawa Hospital Research Institute. Her main areas of clinical and research interest include clinical research for the optimal prevention and treatment strategies for patients with cancer-associated thrombosis, drug-drug interactions with anticoagulants, and obesity-related thromboembolism. She holds a Tier 2 Clinical Research Chair in Cancer and Thromboembolism from the University of Ottawa. She has received research funding from the International Society on Thrombosis and Haemostasis (ISTH), the Canadian Institutes of Health Research (CIHR), The Ottawa Hospital Academic Medical Organization (TOHAMO), and the International Network of VENous Thromboembolism Clinical Research Networks (INVENT). She is currently the Chair of the ISTH (International Society on Thrombosis and Haemostasis) Live Courses Subcommittee of the Education Committee. She was a co-chair of the Hemostasis and Malignancy Subcommittee of the International Society on Thrombosis and Haemostasis from 2018 to 2022.
Selected Publications
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia DA, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M,
Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine. 2018 Feb 15; 378(7):615- 624. [PMID: 29231094].
Lanting V, van Bergen en Henegouwen K, Bosch F, Grosso M, Segers A, Raskob G, Kamphuisen T, Büller H, Verhamme P, Weitz J,? Di Nisio M, Carrier M, van Es N,
Wang TF. Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post-hoc analysis of the Hokusai VTE Cancer study. Journal of Thrombosis and Hemostasis. 2025 Mar 4:S1538-7836(25)00120-5. [PMID: 40049418].
Wang TF, Kou R, Carrier M, Delluc A. Management of catheter-related upper extremity deep vein thrombosis in patients with cancer: a systematic review and meta-analysis. J Thromb Haemost. 2024 Mar;22(3):749-764. [PMID: 38065528].
Wang TF, Clarke A, Awan AA, Tanuseputro P, Carrier M, Sood MM. Hemorrhage risk in direct oral anticoagulant users receiving tamoxifen versus aromatase inhibitors for breast cancer. JAMA Network Open. 2022 Jun 1;5(6):e2219128. [PMID: 35763294].
Wang TF, Khorana AA, Agnelli G, Bloomfield D, Bonaca MP, Büller HR, Connors JM, Goto S, Jing ZC, Kakkar AK, Khder Y, Raskob GE, Soff GA, Verhamme P, Weitz JI, Carrier M. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. Oncologist. 2023 Jul 5;28(7):555-564. [PMID: 37171998].
Diseases, conditions and populations of interest
Research and clinical approaches
